TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02765217
Drug: Lactobacillus reuteri DSM 17938
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
Study: NCT02765217
Drug: Amoxicillin-Clavulanic Acid
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
Study: NCT01700049
Drug: vismodegib (150 mg PO daily)
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Biopsies will be performed on all participants at baseline, week 12 and week 24.
Study: NCT02630836
Drug: XCEL-MT-OSTEO-BETA
Normalized name: Osteo-Poretical
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XCEL-MT-OSTEO-BETA followed by endomedullary nailing
Study: NCT00872885
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg
Study: NCT00084448
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01610739
Drug: Indigocyanine green dye
Normalized name: Indocyanine Green
DrugBank: Indigo (DB16862)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
Study: NCT04111848
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour.
Study: NCT04111848
Drug: ketamine and magnesium
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
Study: NCT03438396
Drug: tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
Study: NCT04051463
Drug: Netarsudil Ophthalmic Solution
Normalized name: netarsudil Ophthalmic Solution
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Netarsudil eye drops instilled once daily
Study: NCT00834860
Drug: peginterferon alpha-2a and ribavirin
Normalized name: peginterferon alfa-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
Study: NCT03063879
Drug: Sofosbuvir 400 mg and daclatasvir 60 mg
Normalized name: sofosbuvir 400 MG
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
Study: NCT00326287
Drug: Ceftobiprole medocaril
Normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00326287
Drug: Ceftriaxone with or without Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01046799
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
Study: NCT00531050
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
Study: NCT00531050
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
Study: NCT00225537
Drug: 4-Methylumbelliferone (Heparvit®)
Normalized name: 4-methylumbelliferone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01280409
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
Study: NCT04397445
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 300 mg
Study: NCT02214368
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention.
Study: NCT00006472
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6 days 1 and 22
Study: NCT00006472
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: taxol
Study: NCT03564301
Drug: Metronidazole 250 MG
Normalized name: metronidazole 250 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
Study: NCT00852566
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Per oral imatinib 400mg once daily (continuous medication)
Study: NCT00852566
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Per oral dasatinib 100mg once daily (continuous medication)
Study: NCT00273481
Drug: dorzolamide 2%/timolol maleate 0.5% fixed combination
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00273481
Drug: timolol maleate 0.5%
Normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00548938
Drug: Gliadel wafer
Normalized name: GLIADEL Wafer 7.7 MG Intracavitary Drug Implant
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implanted at surgery
Study: NCT00548938
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During External Beam Radiation
Study: NCT04384666
Drug: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
Normalized name: naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
Study: NCT00709436
Drug: PMI-150 (intranasal ketamine)
Normalized name: PMI-001
DrugBank: PMI-001 (DB05730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
Study: NCT00003436
Drug: amsacrine
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003436
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003436
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003436
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003436
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003436
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02070302
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
Study: NCT04131543
Drug: Cabozantinib 20 MG
Normalized name: cabozantinib 20 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
Study: NCT04131543
Drug: Cabozantinib 40 MG
Normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
Study: NCT04131543
Drug: Cabozantinib 60 MG
Normalized name: cabozantinib 60 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
Study: NCT00364806
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00364806
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01829087
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT04943159
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
Study: NCT01841775
Drug: interferon α 2b + ribavirin
Normalized name: Interferon α-2b
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks
Study: NCT01011075
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
Study: NCT01011075
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
Study: NCT00891371
Drug: lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Autogel 120mg
Study: NCT02740829
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon will be administered via a nasal dispenser
Study: NCT00003144
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003144
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003144
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01678001
Drug: Xeomin
Normalized name: Xeomin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
Study: NCT01242930
Drug: Imetelstat (7.5 mg/kg)
Normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
Study: NCT01242930
Drug: lenalidomide standard of care
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
Study: NCT01242930
Drug: Imetelstat (9.4 mg/kg)
Normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
Study: NCT02799238
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
Study: NCT00008151
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008151
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00008151
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00008151
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01043120
Drug: Barusiban
Normalized name: Barusiban
DrugBank: Barusiban (DB12292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
Study: NCT01087671
Drug: tafluprost
Normalized name: Tafluprost
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prostaglandin analogue
Study: NCT03487783
Drug: Aripiprazole Oral Solution
Normalized name: Aripiprazole Oral Solution
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole 2-20 mg/day (2-20 mL/day)
Study: NCT02493777
Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules
Normalized name: Methylphenidate Hydrochloride Extended-Release Capsules
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HLD200 doses: 20, 40, 60, 80 or 100 mg
Study: NCT01703884
Drug: ASAQ
Normalized name: Artesunate-Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
Study: NCT00121316
Drug: Pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus Cream 1 %
Study: NCT00580216
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration
Study: NCT00580216
Drug: Avidin
Normalized name: Avidin
DrugBank: Avidin (DB15228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes
Study: NCT01829841
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib 25 mg p.o. qd
Study: NCT01829841
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50 mg p.o. qd
Study: NCT00422981
Drug: AL-108
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg QD
Study: NCT00422981
Drug: AL-108
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg BID
Study: NCT01959035
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
Study: NCT05367479
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-operative, intravenous antibiotic for surgical site infection
Study: NCT02369900
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00160732
Drug: Allogenic islet cells (human, U. Chicago)
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
Study: NCT00587015
Drug: CAT-8015
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60...μg/kg until toxicity supervenes.
Study: NCT01765582
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
Study: NCT01765582
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
Study: NCT01765582
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
Study: NCT01765582
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
Study: NCT01711177
Drug: travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travatan Z is administered to newly diagnosed glaucoma patient
Study: NCT02436889
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02436889
Drug: Tolterodine Tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01765582
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
Study: NCT03106831
Drug: Pituitrin infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
Study: NCT04057469
Drug: Tulobuterol Hydrochloride
Normalized name: tulobuterol hydrochloride
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
Study: NCT01806324
Drug: Losartan + Atorvastatin
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT04442490
Drug: SAGE-217
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 oral capsules.
Study: NCT00004218
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no